A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

Clinical Trial ID NCT01582191

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeted therapies in development for non-small cell lung cancer.	J Carcinog	2013	1.12
2	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.	Lung Cancer	2015	0.84
3	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.	BMC Dermatol	2015	0.81
4	The minority report: targeting the rare oncogenes in NSCLC.	Curr Treat Options Oncol	2014	0.78
5	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.	Oncology	2016	0.75
6	Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.	Clin Genitourin Cancer	2015	0.75
7	Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients.	Oncoscience	2015	0.75
8	Genomic diversity of colorectal cancer: Changing landscape and emerging targets.	World J Gastroenterol	2016	0.75